new drug application
Tonix Pharmaceuticals has submitted a New Drug Application (NDA) to the FDA for TNX-102 SL, a non-opioid, centrally-acting analgesic for fibromyalgia. The NDA is based on two successful Phase 3 studies showing statistically significant pain reduction. TNX-102 SL has been granted Fast Track designation by the FDA, potentially expediting the review process.
Key points:
The company expects an FDA decision on approval in 2025, pending acceptance of the NDA for review.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment